A public-private partnership between the Biomedical Advanced Research and Development Authority (BARDA) and MBio Diagnostics aims to create a COVID-19 serology test capable of providing results within five minutes.
The test is a point-of-care diagnostic that tests for human anti-SARS-CoV-2 antibodies in whole blood samples. Using multiplexed cartridge-based lateral flow, the test is capable of detecting active or past infections, allowing rapid on-site screening of patients in places like drive-thru windows or walk-up testing sites.
The test will utilize MBio’s LightDeck platform and detect both IgG, which is found in the blood after infection and IgM, which forms when the body fights a new infection. That platform mixes low-cost cartridges and intuitive software to assist the health care, veterinary and environmental industries. Specifically, this test will quantify total antibody reactivity to three SARS-CoV-2 antigens and, in so doing, potentially assist immunity assessment as well.
The test is the latest in BARDA’s ever-growing arsenal of COVID-19 medical countermeasures.
Opposition rose this week against a proposal from the U.S. Air Force within the FY…
In order to properly prepare working canines for explosives detection, the Department of Homeland Security…
Through new legislation, U.S. Reps. Michael McCaul (R-TX) and Mike Turner (R-OH) recently placed themselves…
Fearing the potential behind a recent outbreak of avian flu (H5N1), 17 U.S. senators wrote…
Thanks to work by Raytheon, an advanced new ground system for space-based missile warning recently…
According to the latest Elder Fraud Report from the Federal Bureau of Investigation (FBI), 2023…
This website uses cookies.